An α,β-unsaturated acrylate derivative containing a thiazole fragment and its applications
By synthesizing α,β-unsaturated acrylate derivatives containing thiazole fragments, the problem of high or low toxicity but insufficient activity of compounds in the prior art has been solved, providing a highly effective and low-toxicity antifungal drug against plant pathogenic fungi.
Patent Information
- Application Number
- CN202611562730.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-10
- Publication Date
- 2026-11-17
AI Technical Summary
In the existing technology, drugs containing thiazole rings are highly toxic, while compounds containing α,β-unsaturated acrylates, although low in toxicity, are relatively undeveloped, lacking biologically active and safe compounds.
We designed and synthesized α,β-unsaturated acrylate derivatives containing thiazole fragments, and linked the R1, R2, and R3 groups through specific reaction steps to form compounds with broad-spectrum antifungal activity.
The synthesized compound exhibits excellent antifungal activity against plant pathogenic fungi such as apple rot fungus, and the synthetic route is simple, making it suitable for novel, highly efficient, and low-toxicity antifungal agents against plant pathogenic fungi.
Smart Images

Figure CN123106574A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medicinal chemistry, specifically to an α,β-unsaturated acrylate derivative containing a thiazole fragment and its applications. Background Technology
[0002] Currently, major crop diseases and pests are experiencing a severe resurgence. The main diseases include: Fusarium head blight, stripe rust, stem rot, and sheath blight in wheat-growing areas; sheath blight and rice blast in rice-growing areas; and southern rust in corn and sclerotinia stem rot in rapeseed. This severe situation urgently requires effective measures to reduce losses, ensure food security, promote the integration of green pest control with unified prevention and control, incorporate green measures such as highly efficient and low-risk pesticides into service offerings, solidly advance pesticide reduction and efficiency improvement, and strengthen guidance on scientific and safe pesticide use.
[0003] Introducing heterocyclic structures into compounds is a key strategy for developing novel pesticides. Thiazoles (five-membered heterocycles containing sulfur and nitrogen) and their derivative benzothiazole, due to their significant pharmacological activities, have become widely used and important structures in agrochemicals. Thiazole derivatives have wide applications and significant effects in the pesticide field, forming an important series of fungicides, insecticides, and herbicides currently on the market. Representative products include the insecticides thiamethoxam and rosinate, the fungicides fluthiazide and fluopyram, and the herbicide fluprazole. Their excellent performance stems from the effective interference of the thiazole structure with multiple stages of the pathogen life cycle and exhibits diverse biological activities in the pharmaceutical field. Thiazole compounds can interact with various enzymes and receptors in organisms, providing a wide range of pharmacological effects, including anticancer, antibacterial, anti-inflammatory, analgesic, antituberculosis, antidementia, and antidiabetic effects. In pesticide development, compounds containing thiazole structures often exhibit excellent antibacterial effects. For example, by introducing thiazole groups into the modification of succinate dehydrogenase inhibitors (SDHI) fungicides, new reagents such as thifluzamide have been successfully developed, which effectively protect crops from necrotic pathogens.
[0004] α,β-Unsaturated acrylic acid fragments are widely embedded in plant secondary metabolites and fungal metabolites, serving as the core pharmacodynamic skeleton for drug molecule design. They also represent a significant area of research as lead structures for novel, low-toxicity, and green pesticides. This conjugated olefinic acid structure possesses unique Michael addition reaction activity, with pharmacological activities covering core therapeutic areas such as anti-inflammatory, anti-allergic, antibacterial, antiviral, antitumor, and hypoglycemic effects. Cinnamic acid (natural extracts of cinnamon and cassia bark) is a typical natural lead compound containing unsaturated acrylic acid fragments. Its derivative, arvastin, uses the conjugated acrylic acid skeleton as its core, inhibiting allergic inflammatory responses by blocking histamine H1 receptors. It is a first-line, long-acting oral anti-allergy drug widely used in the treatment of allergic rhinitis and urticaria. Ibrutinib contains an α,β-unsaturated acrylamide structure. Relying on the electrophilic double bond of the acrylic acid fragment, it covalently binds to cysteine residues of the BTK protein, irreversibly inhibiting the B-cell proliferation signaling pathway, making it a targeted antitumor drug for the treatment of lymphoma and leukemia. Aryl acrylate natural derivatives, isolated from plants in the Asteraceae family such as yarrow, can effectively inhibit α-glucosidase, block the breakdown and absorption of sugars in the intestine, and lower postprandial blood glucose. They are candidate lead molecules for type 2 diabetes and also possess urease inhibitory activity, which can help improve Helicobacter pylori-related gastric inflammation. Cinnamyl acrylate compounds are often used as lead skeletons for green insecticides. This fragment can activate ryanodine receptors in insects, continuously releasing calcium ions to disrupt insect nerve conduction, exhibiting high contact toxicity against diamondback moths and armyworms. They are easily degraded in the environment and leave no long-term residues, meeting the needs of green pesticide development. At the same time, acrylic acid-derived heterocyclic compounds can induce plant autoimmunity and inhibit the proliferation of tobacco mosaic virus, possessing both bactericidal and antiviral agricultural activities. In addition, unsaturated acrylic acid fragments are key building blocks for chiral drug synthesis. Utilizing stereoselective addition reactions of conjugated double bonds, covalently targeted inhibitors and anti-inflammatory chiral intermediates can be constructed for the industrial synthesis of kinase inhibitors and topical anti-inflammatory agents. The above examples fully demonstrate that α,β-unsaturated acrylic acid fragments have both abundant natural sources, diverse targets, and dual development value in agricultural and medicinal applications, and possess broad development potential in the field of new drug and green insecticide creation.
[0005] Previous studies have shown that compounds containing thiazole rings exhibit good biological activity but also high drug toxicity and are unfriendly to natural organisms. Compounds containing α,β-unsaturated acrylic acid have the advantages of low toxicity, safety, and high efficacy; however, the field of α,β-unsaturated acrylates is relatively unexplored. Therefore, there is an urgent need to design and synthesize a series of compounds with better biological activity, lower toxicity, and safety containing thiazole fragments, and to further elucidate the antibacterial mechanism of these compounds. Summary of the Invention
[0006] The purpose of this invention is to provide an α,β-unsaturated acrylate derivative containing a thiazole fragment and its application, in order to solve the problems mentioned in the background art.
[0007] To achieve the above objectives, the present invention provides the following technical solution:
[0008] An α,β-unsaturated acrylate derivative containing a thiazole fragment has the following general structural formula:
[0009] ;
[0010] Among them, R 1 One or more substituents are selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, and halo-C1-C6 alkyl; when R 1 When there are multiple substituents, R at different positions 1 Same or different;
[0011] R 2 It is selected from any one of substituted or unsubstituted aryl, C1-C8 alkyl, anthracel, and pyridyl; the substituent in the substituted or unsubstituted aryl is selected from one or more of halogen, C1-C6 alkyl, C1-C6 alkoxy, phenoxy, phenyl, and halo-C1-C6 alkyl.
[0012] R 3 It is selected from any one of hydrogen, halogen, and C1-C6 alkyl.
[0013] Furthermore, R 1 It is selected from one or more of hydrogen, fluorine, chlorine, bromine, iodine, methyl, methoxy, and trifluoromethyl;
[0014] R 2 It is selected from any one of substituted or unsubstituted phenyl, 4-phenoxyphenyl, biphenyl, tert-butyl, anthracene-9-yl, pyridin-3-yl, and pyridin-4-yl; the substituent in the substituted or unsubstituted phenyl is selected from one or more of fluorine, chlorine, bromine, iodine, methyl, methoxy, and trifluoromethyl.
[0015] R 3 Selected from hydrogen or methyl.
[0016] Furthermore, R 1 Selected from one or more of hydrogen, fluorine, chlorine, bromine, iodine, and methoxy, preferably, R 1 Selected from methoxy or fluorine atoms;
[0017] R 2 Selected from any one of pyridin-4-yl or substituted phenyl groups;
[0018] R 3 Selected from methyl.
[0019] Another object of the present invention is to provide a method for preparing the above-mentioned α,β-unsaturated acrylate derivative containing a thiazole fragment, comprising the following steps:
[0020] Under a protective atmosphere (such as argon or nitrogen), R 3 Group-substituted 2-phosphonoacetic acid triethyl ester and a base are dissolved in a first organic solvent (such as tetrahydrofuran) and react with R 1 The substituted benzaldehyde (aldehyde substrate) is mixed and reacted to obtain intermediate B; preferably, in this step, the reaction is first stirred at -2 ℃ to 2 ℃ for 20-40 min, and then the corresponding aldehyde substrate is added and stirred at room temperature for 10-12 h overnight.
[0021] ;
[0022] Intermediate B and sodium hydroxide are mixed in an ethanol-water solvent (i.e., a mixed solvent of ethanol and water) and dehydrated to obtain intermediate C; preferably, in this step, the reaction temperature is 60-80 °C and the reaction time is 10-12 h.
[0023] ;
[0024] Under a protective atmosphere, using 4,5-dimethylthiazole as a raw material, it is dissolved with an alkali in a second organic solvent (such as tetrahydrofuran) and then reacted with R. 2 The reaction of substituted formaldehyde (aldehyde substrate) with a group is carried out to obtain intermediate D; preferably, in this step, the reaction is first placed at -80 ℃ to -76 ℃, and after the corresponding aldehyde substrate is added, the mixture is stirred at -80 ℃ to -76 ℃ for 0.5-1.5 h, and then stirred at room temperature for 6-8 h.
[0025] ;
[0026] Intermediate C, catalyst, intermediate D, condensing agent and base are dissolved in a third organic solvent (such as dichloromethane) to carry out a condensation reaction to obtain the target product α,β-unsaturated acrylate derivative; preferably, in this step, the reaction temperature is 20-30 ℃ and the reaction time is 2-3 h;
[0027] ;
[0028] Among them, R 1 R 2 R 3 The definition of R above 1 R 2 R 3 The definitions are the same.
[0029] Furthermore, R 1 The group-substituted benzaldehyde is selected from any one of 4-fluorobenzaldehyde, 4-chlorobenzaldehyde, 4-methoxybenzaldehyde, and 4-methylbenzaldehyde; R 3The group-substituted 2-phosphonoacetic acid triethyl ester is selected from triethyl 2-phosphopropionate; R 1 Group-substituted benzaldehyde, R 3 The molar ratio of triethyl 2-phosphonoacetate with substituted groups to the base is 1:(1.1-1.3):(1.1-1.3).
[0030] Furthermore, R 2 The substituted formaldehyde group is selected from any one of 4-pyridinebenzaldehyde, 4-phenoxybenzaldehyde, and trimethylacetaldehyde; R 2 The molar ratio of group-substituted formaldehyde, 4,5-dimethylthiazole and base is (1.1-1.3):1:(1.1-1.3).
[0031] Furthermore, the catalyst is 4-dimethylaminopyridine (DMAP).
[0032] Furthermore, the condensing agent is any one of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBT), and N-hydroxysuccinimide (NHS).
[0033] Furthermore, the base is selected from any one of triethylamine, pyridine, potassium carbonate, cesium carbonate, sodium hydride, and n-butyllithium.
[0034] Furthermore, after the condensation reaction is completed, the process also includes extraction, drying, filtration, vacuum distillation, and column chromatography separation.
[0035] Preferably, the extraction specifically involves: after the reaction is completed, extraction is performed sequentially using unsaturated ammonium chloride solution, saturated sodium bicarbonate solution, saturated saline solution, and ethyl acetate or dichloromethane; the column chromatography separation specifically involves: using 100-200 mesh silica gel powder as the eluent, and a mixture of petroleum ether and ethyl acetate as the eluent; the drying reagent used is anhydrous sodium sulfate.
[0036] The reaction process of this invention can be determined using thin-layer chromatography plates to pinpoint the reaction endpoint.
[0037] Another object of the present invention is to provide the use of the above-mentioned α,β-unsaturated acrylate derivative containing a thiazole fragment in the preparation of antifungal drugs.
[0038] Furthermore, the fungi include one or more of the following: apple rot fungus, sclerotium rot fungus, rhizoctonia solani fungus, Alternaria alternata, wheat scab, Curvularia crescentis, Phytophthora capsici, and Sclerotium sclerotiorum.
[0039] Another object of the present invention is to provide an antifungal drug comprising the above-mentioned α,β-unsaturated acrylate derivatives containing thiazole fragments as the active pharmaceutical ingredient.
[0040] The α,β-unsaturated acrylate derivatives containing thiazole fragments provided by this invention exhibit excellent broad-spectrum antifungal activity against plant pathogenic fungi such as *Aureobasidium argentea*, *Sclerotinia sclerotiorum*, *Rhizoctonia solani*, *Alternaria alternata*, *Fusarium graminearum*, *Curvularia crescentis*, *Phytophthora capsici*, and *Sclerotium sclerotiorum*. Furthermore, the synthetic route is simple, and these derivatives have significant development value as novel, highly efficient, and low-toxicity antifungal agents or active ingredients in antifungal drugs. Detailed Implementation
[0041] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0042] The following embodiments are examples of the present invention in practical applications and are for illustrative purposes only, and are not intended to limit the scope of the invention. It should be noted that, unless otherwise specified, the experimental methods in the following embodiments are conventional methods in the art; and the reagents or materials used, unless otherwise specified, are commercially available.
[0043] In this embodiment of the invention, the column chromatography conditions are as follows: 100-200 mesh silica gel powder is used. The molar numbers indicated in this embodiment of the invention represent the amount of the substance used in the reaction system.
[0044] The synthetic routes of the compounds involved in the following examples are as follows:
[0045] ;
[0046] Among them, R 1 R 2 R 3 The determination is based on the raw materials used in each embodiment.
[0047] Example 1: This example provides a compound A1, the synthesis steps of which are as follows:
[0048] (1) Triethyl 2-phosphate acetate (12 mmol) was added to a tetrahydrofuran (50 mL) solution of sodium hydride (12 mmol) at 0 °C under a N2 atmosphere. The mixture was stirred for 30 minutes, and then benzaldehyde (10 mmol) was added and stirred overnight at room temperature. The reaction was confirmed to be complete by TLC monitoring. The reaction was quenched by adding saturated ammonium chloride solution (20 mL). The resulting mixture was concentrated by rotary evaporation and then extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography (eluent: ethyl acetate / petroleum ether = 1:20) to obtain intermediate B.
[0049] (2) Intermediate B (10 mmol) was added to sodium hydroxide (25 mmol) in an ethanol / water mixture (volume ratio 7:3, 25 mL) and stirred overnight at 60 °C. The reaction was confirmed to be complete by TLC monitoring. The pH of the system was adjusted to 1 by adding concentrated hydrochloric acid (12 mol / L) to quench the reaction. The mixture was then extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness under reduced pressure to obtain intermediate C.
[0050] (3) Under a N2 atmosphere, 20 mmol of 4,5-dimethylthiazole was dissolved in 50 mL of ultra-dry tetrahydrofuran. The mixture was stirred at -78 °C for 30 minutes. Then, 10 mL of n-butyllithium was added to the reaction mixture and the stirring continued for another 30 minutes. 24 mmol of benzaldehyde was added to the reaction mixture and the mixture was stirred at -78 °C for 1 hour. The mixture was then removed and stirred at room temperature for 4-6 hours. The reaction was confirmed to be complete by TLC monitoring. 50 mL of saturated ammonium chloride solution was added to quench the reaction. The resulting mixture was concentrated by rotary evaporation and then extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with 50 mL of saturated sodium bicarbonate and 50 mL of saturated brine, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography (eluent: ethyl acetate / petroleum ether = 1:6) to obtain intermediate D.
[0051] (4) Intermediate C (0.6 mmol), intermediate D (0.4 mmol), EDCI (0.6 mmol), DMAP (0.6 mmol), and triethylamine (100 μL) were dissolved in dichloromethane solution (5 mL) and stirred at room temperature for 1–2 hours. The reaction was confirmed to be complete by TLC monitoring. Then, the target product was separated by preparative thin-layer chromatography (PTLC) (developing solvent: ethyl acetate / petroleum ether = 1:2) to obtain compound A1.
[0052] Compound A1: (E)-2-methyl-3-phenylacrylate-(4,5-dimethylthiazolyl-2-yl)(phenyl)methyl ester, with the structural formula shown below:
[0053] ;
[0054] White solid, yield: 85%; mp: 74.9-75.9 ℃; 1 H NMR (400 MHz, CDCl3) δ7.88 (s, 1H), 7.59 - 7.55 (m, 2H), 7.46 - 7.42 (m, 3H), 7.42 - 7.38 (m, 3H),7.37 - 7.32 (m, 2H), 7.17 (s, 1H), 2.33 (s, 6H), 2.22 (d, J = 1.5 Hz, 3H). 13 CNMR (101 MHz, CDCl3) δ 167.07, 164.58, 148.55, 140.19, 138.55, 135.71,129.79, 128.74, 128.63, 128.60, 128.46, 127.95, 127.18, 127.10, 75.28, 14.80,14.19, 11.30. HRMS (ESI) calculated for C 22 H 22 NO2S [M+H] + , 364.1371; found,364.1371.
[0055] Example 2: This example provides a compound A2, which differs from Example 1 only in that benzaldehyde in step (3) is replaced with 4-phenoxybenzaldehyde. Compound A2 is obtained as: (E)-2-methyl-3-phenylacrylate-(4,5-dimethylthiazolyl-2-yl)(4-phenoxyphenyl)methyl ester, with the following structural formula:
[0056] ;
[0057] Pale-yellow viscose oil, yield: 80%; 1H NMR (400 MHz, CDCl3) δ 7.82(s, 1H), 7.41 - 7.36 (m, 4H), 7.33 (d, J = 3.0 Hz, 1H), 7.31 (d, J = 3.4 Hz,2H), 7.30 - 7.27 (m, 2H), 7.23 (s, 1H), 7.11 (s, 1H), 7.08 (t, J = 7.4 Hz,1H), 7.02 (d, J = 7.8 Hz, 2H), 6.93 (d, J = 7.7 Hz, 1H), 2.30 (s, 6H), 2.17(d, J = 1.6 Hz, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.91, 164.17, 157.74,156.81, 148.63, 140.61, 140.34, 135.61, 130.16, 129.88, 128.74, HRMS (ESI) calculated for C 28 H 26 NO3S [M+H] + , 456.1633; found, 456.1633.
[0058] Example 3: This example provides a compound A3, which differs from Example 1 only in that benzaldehyde in step (3) is replaced with 4-phenylbenzaldehyde. Compound A3 is obtained as: (E)-2-methyl-3-phenylacrylate-([1,1'-biphenyl]-4-yl)(4,5-dimethylthiazolyl-2-yl)methyl ester, with the following structural formula:
[0059] ;
[0060] White solid, yield: 82%; mp: 121.6-122.6 ℃; 1H NMR (400 MHz, CDCl3) δ7.90 (s, 1H), 7.64 (s, 4H), 7.60 (d, J = 7.7 Hz, 2H), 7.45 (t, J = 8.0 Hz, 6H), 7.37 (d, J = 7.0 Hz, 2H), 7.21 (s, 1H), 2.35 (s, 3H), 2.35 (s, 3H), 2.24(s, 3H). 13 C NMR (101 MHz, CDCl3) δ 167.14, 164.55, 148.66, 141.60, 140.64,140.30, 137.52, 135.73, 129.84, 128.85, 128.65, 128.49, 127.97, 127.70,127.54, 127.20, 127.16, 75.18, 14.85, 14.25, 11.34. HRMS (ESI) calculated forC 28 H 26 NO2S [M+H] + , 440.1684; found, 440.1684.
[0061] Example 4: This example provides a compound A4, which differs from Example 1 only in that benzaldehyde in step (3) is replaced with trimethylacetaldehyde. Compound A4 is obtained as: (E)-2-methyl-3-phenylacrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0062] ;
[0063] White solid, yield: 85%; mp: 74.4-75.4 ℃; 1 H NMR (400 MHz, CDCl3) δ7.78 (s, 1H), 7.41 (d, J = 6.3 Hz, 4H), 7.35 - 7.30 (m, 1H), 5.85 (s, 1H), 2.31 (d, J = 2.0 Hz, 6H), 2.17 (d, J = 1.5 Hz, 3H), 1.09 (s, 9H). 13C NMR (101MHz, CDCl3) δ 167.45, 163.34, 147.65, 139.71, 135.76, 129.74, 128.47, 128.40,128.20, 126.02, 80.84, 35.39, 26.14, 14.76, 14.10, 11.20. HRMS (ESI)calculated for C 20 H 26 NO2S [M+H] + , 344.1684; found, 344.1684.
[0064] Example 5: This example provides a compound A5, which differs from Example 1 only in that benzaldehyde in step (3) is replaced with 9-anthracenecarboxaldehyde. Compound A5 is obtained: (E)-2-methyl-3-phenylacrylate-(anthracene-9-yl)(4,5-dimethylthiazolyl-2-yl)methyl ester.
[0065] ;
[0066] Reddish-brown solid, yield: 78%; mp: 137.3-138.3 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 4.4 Hz, 2H), 8.69 (s, 1H), 8.54 (s, 1H), 8.04 (d, J =8.3 Hz, 2H), 7.88 (d, J = 1.5 Hz, 1H), 7.58 (t, J = 7.6 Hz, 2H), 7.52 - 7.46(m, 2H), 7.38 (d, J = 4.4 Hz, 4H), 7.35 - 7.30 (m, 1H), 2.28 (s, 3H), 2.27(s, 3H), 2.20 (d, J = 1.5 Hz, 3H). 13 C NMR (101 MHz, CDCl3) δ 167.65, 164.70,148.84, 140.41, 135.80, 131.76, 130.52, 130.03, 129.78, 129.39, 128.79,128.55, 128.44, 128.00, 127.26, 126.59, 125.06, 70.96, 14.90. HRMS (ESI)calculated for C30 H 26 NO2S [M+H] + , 464.1684; found, 464.1686.
[0067] Example 6: This example provides a compound A6, which differs from Example 1 only in that benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A6 is obtained as: (E)-2-methyl-3-phenylacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridine-4-yl)methyl ester, with the following structural formula:
[0068] ;
[0069] Reddish-brown solid, yield: 81%; mp: 72.4-73.4 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 5.8 Hz, 2H), 7.83 (s, 1H), 7.45 - 7.31 (m, 6H), 7.28 (d, J = 7.1 Hz, 1H), 7.05 (s, 1H), 2.26 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.49, 162.36, 149.86, 148.67, 146.97, 140.56,135.22, 129.69, 128.66, 128.34, 127.57, 127.21, 121.42, 73.52, 14.51, 14.02,11.00. HRMS (ESI) calculated for C 21 H 21 N₂O₂S [M+H] + , 365.1323; found, 365.1317.
[0070] Example 7: This example provides a compound A7, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-methoxybenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A7 is obtained as: (E)-3-(4-methoxyphenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridine-4-yl)methyl ester, with the following structural formula:
[0071] ;
[0072] Pale-yellow solid, yield: 82%; mp: 53.3-54.3 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 6.2 Hz, 2H), 7.80 (s, 1H), 7.46 - 7.37 (m, 4H), 7.06(s, 1H), 6.92 (d, J = 9.0 Hz, 2H), 3.81 (s, 3H), 2.30 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 167.05, 162.63, 160.10, 149.88,148.81, 147.36, 140.56, 131.74, 128.00, 127.69, 124.92, 121.59, 113.99,73.54, 55.32, 14.69, 14.17, 11.27. HRMS (ESI) calculated for C 22 H 23 N₂O₃S [M+H] + , 395.1429; found, 395.1427.
[0073] Example 8: This example provides a compound A8, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-chlorobenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A8 is obtained: (E)-3-(4-chlorophenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0074] ;
[0075] Pale-yellow solid, yield: 82%; mp: 92.2-93.2 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.58 (d, J = 6.1 Hz, 2H), 7.75 (s, 1H), 7.39 (d, J = 5.8 Hz, 2H), 7.32 (s, 4H), 7.04 (s, 1H), 2.28 (s, 3H), 2.26 (s, 3H), 2.14 (s, 3H). 13C NMR(101 MHz, CDCl3) δ 166.54, 162.28, 150.03, 148.89, 146.98, 139.35, 134.72,133.82, 131.05, 128.74, 127.98, 127.79, 121.52, 73.73, 14.69, 14.12, 11.26.HRMS (ESI) calculated for C 21 H 20 ClN2O2S [M+H] + , 399.0934; found, 399.0933.
[0076] Example 9: This example provides a compound A9, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-fluorobenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A9 is obtained: (E)-3-(4-fluorophenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0077] ;
[0078] Pale-yellow solid, yield: 83%; mp: 94.3-95.3 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 6.2 Hz, 2H), 7.78 (s, 1H), 7.39 (dd, J = 10.3, 5.6 Hz, 4H), 7.09 (s, 1H), 7.06 (d, J = 5.6 Hz, 2H), 2.29 (s, 3H), 2.27 (s, 3H), 2.16 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.65, 162.68 (d, J = 251.49 Hz), 162.36,150.00, 148.84, 147.03, 139.53, 131.73 (d, J = 8.08 Hz), 131.49 (d, J = 4.04Hz), 127.75, 127.15, 127.13, 121.51, 115.57 (d, J = 21.21 Hz), 73.67, 14.66,14.03, 11.22. 19F NMR (377 MHz, CDCl3) δ -111.29. HRMS (ESI) calculated forC 21 H 20 FN2O2S [M+H] + , 383.1229; found, 383.1231.
[0079] Example 10: This example provides a compound A10, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-bromobenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A10 is obtained: (E)-3-(4-bromophenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0080] ;
[0081] Pale-yellow viscose oil, yield: 81%; 1 H NMR (400 MHz, CDCl3) δ 8.53(d, J = 6.1 Hz, 2H), 7.67 (s, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 6.2Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 6.98 (s, 1H), 2.24 (s, 3H), 2.21 (s, 3H), 2.08 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.53, 162.28, 150.15, 148.89,146.87, 139.38, 134.26, 131.70, 131.27, 128.11, 127.78, 123.02, 121.49,73.76, 14.72, 14.15, 11.28. HRMS (ESI) calculated for C 21 H 20 BrN2O2S [M+H] + ,443.0429; found, 443.0429.
[0082] Example 11: This example provides a compound A11, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-methylbenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A11 is obtained as: (E)-2-methyl-3-(p-tolyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0083] ;
[0084] Pale-yellow viscose oil, yield: 82%; 1 H NMR (400 MHz, CDCl3) δ 8.61(d, J = 5.8 Hz, 2H), 7.83 (s, 1H), 7.43 (d, J = 5.2 Hz, 2H), 7.34 (d, J = 7.9Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 7.07 (s, 1H), 2.36 (s, 3H), 2.31 (s, 3H), 2.29 (s, 3H), 2.20 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.91, 162.58, 149.99,148.81, 147.19, 140.85, 139.03, 132.57, 129.94, 129.22, 127.70, 126.34,121.54, 73.60, 21.36, 14.69, 14.18, 11.25. HRMS (ESI) calculated forC 22 H 23 N₂O₂S [M+H] + , 379.1480; found, 379.1478.
[0085] Example 12: This example provides a compound A12, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 4-iodobenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A12 is obtained: (E)-3-(4-iodophenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0086] ;
[0087] Pale-yellow viscose oil, yield: 78%; 1 H NMR (400 MHz, CDCl3) δ 8.58(d, J = 6.2 Hz, 2H), 7.71 (s, 1H), 7.69 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 6.1Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 7.04 (s, 1H), 2.28 (s, 3H), 2.26 (s, 3H), 2.13 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.46, 162.25, 150.05, 148.85,146.88, 139.47, 137.63, 134.77, 131.37, 128.17, 127.77, 121.50, 94.98, 73.71,14.73, 14.19, 11.30. HRMS (ESI) calculated for C 21 H 20 IN2O2S [M+H] + , 491.0290;found, 491.0288.
[0088] Example 13: This example provides a compound A13, which differs from Example 1 only in that benzaldehyde in step (1) is replaced with 3-fluorobenzaldehyde, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound A13 is obtained: (E)-3-(3-fluorophenyl)-2-methacrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0089] ;
[0090] Pale-yellow solid, yield: 83%; mp: 89.7-90.7 ℃; 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 6.1 Hz, 2H), 7.77 (s, 1H), 7.42 (d, J = 6.2 Hz, 2H), 7.38 - 7.32 (m, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.11 (d, J = 9.9 Hz, 1H), 7.06 (s, 1H), 7.02 (td, J = 8.4, 2.5 Hz, 1H), 2.31 (s, 3H), 2.29 (s, 3H), 2.17 (d,J = 1.6 Hz, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.51, 162.62 (d, J = 247.45 Hz), 162.28, 150.10, 148.90, 146.91, 139.32 (d, J = 3.03 Hz), 137.49 (d, J = 8.08Hz), 130.05 (d, J = 8.08 Hz), 128.63, 127.83, 125.60 (d, J = 3.03 Hz), 121.51, 116.36 (d, J = 22.22 Hz), 115.67 (d, J = 21.21 Hz), 73.79, 14.72,14.15, 11.30. 19 F NMR (377 MHz, DMSO) δ -112.73. HRMS (ESI) calculated forC 21 H 20 FN2O2S [M+H] + , 383.1229; found, 383.1228.
[0091] Example 14: This example provides a compound R1, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate. Compound R1 is obtained: methyl cinnamic acid-(4,5-dimethylthiazol-2-yl)(phenyl) ester, with the following structural formula:
[0092] ;
[0093] White solid, yield: 88%; mp: 65.9-66.9 ℃; 1H NMR (600 MHz, Chloroform-d) δ 7.79 (d, J = 16.1 Hz, 1H), 7.54 (d, J = 5.7 Hz, 4H), 7.39 (s,5H), 7.34 (d, J = 6.3 Hz, 1H), 7.14 (s, 1H), 6.58 (dd, J = 16.0, 2.5 Hz, 1H),2.32 (d, J = 2.7 Hz, 6H). 13 C NMR (101 MHz, CDCl3) δ 165.46, 164.27, 148.59,146.08, 138.37, 134.28, 130.55, 128.94, 128.69, 128.63, 128.25, 127.21,117.45, 74.75, 14.77, 11.27. HRMS (ESI) calculated for C 21 H 20 NO2S [M+H] + ,350.1214; found, 350.1213.
[0094] Example 15: This example provides a compound R2, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with 4-phenoxybenzaldehyde. Compound R2 is obtained: methyl cinnamic acid-(4,5-dimethylthiazol-2-yl)(4-phenoxyphenyl) ester, with the following structural formula:
[0095] ;
[0096] Pale-yellow viscose oil, yield: 85%; 1H NMR (600 MHz, Chloroform-d) δ7.78 (d, J = 16.0 Hz, 1H), 7.54 (dd, J = 6.7, 3.0 Hz, 2H), 7.43 - 7.38 (m,3H), 7.33 (t, J = 7.8 Hz, 3H), 7.28 (d, J = 7.6 Hz, 1H), 7.24 (s, 1H), 7.11(d, J = 5.2 Hz, 2H), 7.06 - 7.01 (m, 2H), 6.95 (m, 1H), 6.56 (d, J = 15.9 Hz,1H), 2.50 - 2.29 (m, 6H). 13 C NMR (101 MHz, CDCl3) δ 165.43, 163.88, 157.52,156.81, 148.60, 146.23, 140.24, 134.19, 130.62, 130.02, 129.80, 128.95,128.29, 127.44, 123.49, 121.89, 119.08, 118.62, 117.52, 117.26, 74.24, 14.77,11.33. HRMS (ESI) calculated for C 27 H 24 NO3S [M+H] + , 442.1477; found, 442.1477.
[0097] Example 16: This example provides a compound R3, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with 4-phenylbenzaldehyde. Compound R3 is obtained: cinnamic acid-([1,1'-biphenyl]-4-yl)-(4,5-dimethylthiazol-2-yl)methyl ester, with the following structural formula:
[0098] ;
[0099] White solid, yield: 85%; mp: 126.1-127.1 ℃; 1H NMR (600 MHz, Chloroform-d) δ 7.81 (d, J = 16.0 Hz, 1H), 7.63 - 7.52 (m, 8H), 7.43 (t, J =7.7 Hz, 2H), 7.41 - 7.39 (m, 3H), 7.36 (d, J = 7.3 Hz, 1H), 7.18 (s, 1H), 6.59 (d, J = 16.0 Hz, 1H), 2.33 (s, 6H). 13 C NMR (101 MHz, CDCl3) δ 165.55,164.18, 148.68, 146.20, 141.61, 140.63, 137.29, 134.24, 130.62, 128.97,128.82, 128.29, 127.71, 127.51, 127.27, 127.20, 117.38, 74.64, 14.85, 11.35.HRMS (ESI) calculated for C 27 H 24 NO2S [M+H] + , 426.1527; found, 426.1525.
[0100] Example 17: This example provides a compound R4, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R4 is: cinnamic acid-1-(4,5-dimethylthiazol-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0101] ;
[0102] White solid, yield: 85%; mp: 77.7-78.7 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 7.72 (d, J = 16.0 Hz, 1H), 7.52 (t, J = 4.8 Hz, 2H), 7.36 (t,J = 3.4 Hz, 3H), 6.52 (d, J = 16.0 Hz, 1H), 5.85 (s, 1H), 2.29 (d, J = 8.6Hz, 6H), 1.07 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 164.82, 161.94, 146.67,144.56, 133.27, 129.39, 127.84, 127.13, 124.97, 116.64, 79.21, 34.22, 25.04,13.71, 10.11. HRMS (ESI) calculated for C 19 H 24 NO2S [M+H] + , 330.1527; found,330.1526.
[0103] Example 18: This example provides a compound R5, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with 9-anthracene carboxaldehyde. Compound R5 is obtained: cinnamic acid (anthracene-9-yl)-(4,5-dimethylthiazolyl-2-yl)methyl ester, with the following structural formula:
[0104] ;
[0105] Yellow solid, yield: 80%; mp: 163.2-164.2 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 8.68 (s, 1H), 8.64 (d, J = 8.9 Hz, 2H), 8.53 (s, 1H), 8.03(d, J = 8.4 Hz, 2H), 7.75 (d, J = 16.0 Hz, 1H), 7.57 - 7.53 (m, 2H), 7.50 -7.45 (m, 4H), 7.36 - 7.32 (m, 3H), 6.60 (d, J = 16.0 Hz, 1H), 2.28 (s, 3H), 2.24 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 165.98, 164.69, 148.64, 146.11,134.31, 134.13, 133.56, 131.69, 130.45, 130.04, 129.30, 128.86, 128.56,128.24, 128.17, 127.36, 127.24, 126.57, 125.01, 117.50, 70.42, 14.79, 11.22.HRMS (ESI) calculated for C 29 H 24 NO2S [M+H] + , 450.1527; found, 450.1526.
[0106] Example 19: This example provides a compound R6, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with 3-pyridinecarboxaldehyde. Compound R6 is obtained: methyl cinnamic acid-(4,5-dimethylthiazol-2-yl)(pyridin-3-yl) ester, with the following structural formula:
[0107] ;
[0108] Yellow solid, yield: 82%; mp: 69.4-70.4 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 8.78 (s, 1H), 8.58 (d, J = 2.8 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.78 (d, J = 15.8 Hz, 1H), 7.54 (t, J = 3.6 Hz, 2H), 7.42 - 7.36 (m,3H), 7.30 (dd, J = 8.0, 4.8 Hz, 1H), 7.14 (s, 1H), 6.55 (d, J = 16.1 Hz, 1H), 2.33 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 165.30, 162.84, 149.84,148.91, 146.59, 135.05, 134.10, 134.06, 130.72, 128.97, 128.30, 127.54,123.44, 116.92, 72.67, 14.73, 11.26. HRMS (ESI) calculated for C 20 H 19 N₂O₂S [M+H] + ,351.1167; found, 351.1167.
[0109] Example 20: This example provides a compound R7, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate, and benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R7 is obtained: methyl cinnamic acid-(4,5-dimethylthiazol-2-yl)(pyridin-4-yl) ester, with the following structural formula:
[0110] ;
[0111] Yellow solid, yield: 82%; mp: 71.2-72.2 ℃; 1 H NMR (400 MHz, CDCl3) δ8.59 (d, J = 6.2 Hz, 2H), 7.79 (d, J = 16.0 Hz, 1H), 7.53 (dd, J = 6.8, 2.7Hz, 2H), 7.41 (d, J = 6.2 Hz, 2H), 7.39 - 7.36 (m, 2H), 7.36 (d, J = 1.2 Hz, 1H), 7.07 (s, 1H), 6.56 (d, J = 16.0 Hz, 1H), 2.29 (s, 3H), 2.28 (s, 3H). 13 CNMR (101 MHz, CDCl3) δ 165.20, 162.23, 150.12, 148.88, 146.86, 146.83,133.97, 130.83, 128.99, 128.33, 127.88, 121.52, 116.66, 73.16, 14.73, 11.30.HRMS (ESI) calculated for C 20 H 19N₂O₂S [M+H] + ,351.1167; found, 351.1167.
[0112] Example 21: This example provides a compound R8, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-methoxybenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. Compound R8 is obtained: (E)-3-(3-methoxyphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0113] ;
[0114] Yellow solid, yield: 80%; mp: 61.7-62.7 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 7.69 (d, J = 15.9 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.13 (d,J = 7.7 Hz, 1H), 7.05 (s, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.51 (d, J = 16.0Hz, 1H), 5.84 (s, 1H), 3.83 (s, 3H), 2.32 - 2.28 (m, 6H), 1.07 (s, 9H). 13 CNMR (101 MHz, CDCl3) δ 165.91, 162.94, 159.91, 147.75, 145.57, 135.65,129.91, 126.08, 120.98, 117.94, 116.45, 112.88, 80.26, 55.34, 35.27, 26.09,14.80, 11.22. HRMS (ESI) calculated for C 20 H 26 NO3S [M+H] + ,360.1633; found,360.1633.
[0115] Example 22: This example provides a compound R9, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-chlorobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R9 is: (E)-3-(3-chlorophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0116] ;
[0117] White solid, yield: 80%; mp: 75.9-76.9 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 7.64 (d, J = 16.0 Hz, 1H), 7.52 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.33 (dt, J = 15.4, 7.9 Hz, 2H), 6.52 (d, J = 16.0 Hz, 1H), 5.83 (s,1H), 2.30 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 164.46, 161.73,146.76, 142.91, 135.14, 133.94, 129.26, 129.12, 126.87, 125.34, 125.07,118.19, 79.48, 34.24, 25.05, 13.73, 10.15. HRMS (ESI) calculated forC 19 H 23 ClNO2S [M+H] + ,364.1138; found, 364.1138.
[0118] Example 23: This example provides a compound R10, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-(trifluoromethyl)benzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R10 is: (E)-3-(3-trifluoromethylphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0119] ;
[0120] Pale-yellow solid, yield: 80%; mp: 64.5-65.5 ℃; 1 H NMR (600 MHz, Chloroform-d) δ 7.78 (s, 1H), 7.74 - 7.68 (m, 2H), 7.63 (d, J = 7.8 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 6.59 (d, J = 16.0 Hz, 1H), 5.84 (s, 1H), 2.30 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 165.36, 162.65, 147.81, 143.70,135.14, 131.50 (q, J = 32.32 Hz), 131.22, 131.21, 127.84, 126.77 (q, J = 3.03Hz), 126.12, 125.13 (q, J = 273.71 Hz), 124.66 (q, J = 4.04 Hz), 119.73,80.57, 35.26, 26.06, 14.74, 11.14. 19 F NMR (376 MHz, CDCl3) δ -62.92. HRMS(ESI) calculated for C 20 H 23 F3NO2S [M+H] + ,398.1401; found, 398.1402.
[0121] Example 24: This example provides a compound R11, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-fluorobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R11 is: (E)-3-(3-fluorophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0122] ;
[0123] Yellow solid, yield: 80%; mp: 83.2-84.2 ℃; 1H NMR (600 MHz, Chloroform-d) δ 7.66 (d, J = 15.9 Hz, 1H), 7.37 - 7.32 (m, 1H), 7.29 (d, J =7.7 Hz, 1H), 7.23 (d, J = 9.1 Hz, 1H), 7.07 (t, J = 7.0 Hz, 1H), 6.51 (d, J =16.0 Hz, 1H), 5.83 (s, 1H), 2.30 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 165.52, 163.02 (d, J = 247.45 Hz), 162.75, 147.78, 144.15 (d, J =3.03 Hz), 136.58 (d, J = 7.07 Hz), 130.45 (d, J = 7.07 Hz), 126.09, 124.18(d, J = 3.03 Hz), 119.13, 117.28 (d, J = 21.21 Hz), 114.40 (d, J = 22.22 Hz), 80.46, 35.25, 26.06, 14.74, 11.15. 19 F NMR (376 MHz, CDCl3) δ -112.43. HRMS(ESI) calculated for C 19 H 23 FNO2S [M+H] + ,348.1433; found, 348.1433.
[0124] Example 25: This example provides a compound R12, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-bromobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R12 is: (E)-3-(3-bromophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0125] ;
[0126] Pale-yellow solid, yield: 80%; mp: 64.7-65.7 ℃; 1H NMR (600 MHz, Chloroform-d) δ 7.68 (s, 1H), 7.63 (d, J = 16.0 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.24 (d, J = 7.9 Hz, 1H), 6.51 (d, J = 16.0Hz, 1H), 5.83 (s, 1H), 2.30 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ165.51, 162.77, 147.77, 143.89, 136.39, 133.23, 130.84, 130.44, 126.84,126.15, 123.05, 119.18, 80.52, 35.26, 26.08, 14.81, 11.24. HRMS (ESI)calculated for C 19 H 23 BrNO2S [M+H] + ,408.0633; found, 408.0632.
[0127] Example 26: This example provides a compound R13, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-methylbenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R13 is: (E)-3-(3-methylphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0128] ;
[0129] Pale-yellow viscose oil, yield: 80%; 1H NMR (600 MHz, Chloroform-d) δ7.70 (d, J = 16.0 Hz, 1H), 7.35 (d, J = 10.2 Hz, 2H), 7.27 (t, J = 7.5 Hz,1H), 7.20 (d, J = 7.6 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 5.84 (s, 1H), 2.37(s, 3H), 2.30 (d, J = 5.3 Hz, 6H), 1.08 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ165.96, 163.07, 147.73, 145.80, 138.56, 134.31, 131.28, 128.83, 128.79,126.00, 125.42, 117.47, 80.25, 35.28, 26.09, 21.30, 14.77, 11.17. HRMS (ESI)calculated for C 20 H 26 NO2S [M+H] + ,344.1684; found, 344.1685.
[0130] Example 27: This example provides a compound R14, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-methoxybenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R14 is (E)-3-(2-methoxyphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0131] ;
[0132] Pale-yellow solid, yield: 80%; mp: 63.5-64.5 ℃; 1H NMR (600 MHz, Chloroform-d) δ 8.05 (d, J = 16.1 Hz, 1H), 7.54 - 7.51 (m, 1H), 7.35 (t, J =8.0 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.61 (d, J =16.1 Hz, 1H), 5.84 (s, 1H), 3.88 (s, 3H), 2.30 (d, J = 5.1 Hz, 6H), 1.07 (s,9H). 13 C NMR (101 MHz, CDCl3) δ 166.47, 163.30, 158.47, 147.67, 141.15,131.63, 129.10, 125.95, 123.38, 120.70, 118.07, 111.20, 80.09, 55.52, 35.27,26.10, 14.76, 11.17. HRMS (ESI) calculated for C 20 H 26 NO3S [M+H] + ,360.1633;found, 360.1637.
[0133] Example 28: This example provides a compound R15, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-chlorobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R15 is: (E)-3-(2-chlorophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0134] ;
[0135] White solid, yield: 80%; mp: 62.1-63.1 ℃; 1H NMR (600 MHz, Chloroform-d) δ 8.17 (d, J = 16.0 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.41 (d,J = 7.7 Hz, 1H), 7.33 - 7.27 (m, 2H), 6.51 (d, J = 16.0 Hz, 1H), 5.84 (s, 1H), 2.31 (s, 6H), 1.08 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 165.40, 162.86,147.75, 141.35, 135.10, 132.59, 131.19, 130.20, 127.68, 127.08, 126.10,120.22, 80.52, 35.28, 26.07, 14.76, 11.18. HRMS (ESI) calculated forC 19 H 23 ClNO2S [M+H] + ,364.1138; found, 364.1138.
[0136] Example 29: This example provides a compound R16, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-(trifluoromethyl)benzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R16 is: (E)-3-(2-trifluoromethylphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0137] ;
[0138] Pale-yellow solid, yield: 80%; mp: 66.6-67.6 ℃; 1H NMR (600 MHz, Chloroform-d) δ 8.15 (d, J = 15.7 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.70 (d,J = 7.9 Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 6.48 (d,J = 15.7 Hz, 1H), 5.83 (s, 1H), 2.31 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 163.90, 161.76, 146.72, 139.91 (q, J = 2.02 Hz), 132.16 (q, J = 2.02Hz), 131.08, 127.98 (q, J = 30.3 Hz), 127.53, 126.84, 125.18 (q, J = 6.06Hz), 122.91 (q, J = 274.72 Hz), 120.85, 79.67, 34.27, 25.00, 13.72, 10.13. 19 FNMR (376 MHz, CDCl3) δ -58.88. HRMS (ESI) calculated for C 20 H 23 F3NO2S [M+H] + ,398.1401; found, 398.1401.
[0139] Example 30: This example provides a compound R17, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-fluorobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R17 is: (E)-3-(2-fluorophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0140] ;
[0141] Pale-yellow solid, yield: 80%; mp: 84.3-85.3 ℃; 1H NMR (600 MHz, Chloroform-d) δ 7.86 (d, J = 16.2 Hz, 1H), 7.55 (t, J = 6.9 Hz, 1H), 7.35 (q,J = 7.9, 6.8 Hz, 1H), 7.21 - 7.13 (m, 1H), 7.09 (t, J = 9.4 Hz, 1H), 6.62 (d,J = 16.2 Hz, 1H), 5.84 (s, 1H), 2.30 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 165.76, 162.90, 161.41 (d, J = 255.53 Hz), 147.74, 138.20 (d, J =3.03 Hz), 131.86 (d, J = 8.08 Hz), 129.19 (d, J = 3.03 Hz), 126.08, 124.45(d, J = 4.04 Hz), 122.44 (d, J = 11.11 Hz), 120.23 (d, J = 6.06 Hz), 116.21(d, J = 22.22 Hz), 80.45, 35.27, 26.07, 14.75, 11.17. 19 F NMR (376 MHz, CDCl3)δ -114.15. HRMS (ESI) calculated for C 19 H 23 FNO2S [M+H] + ,348.1433; found,348.1434.
[0142] Example 31: This example provides a compound R18, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-bromobenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R18 is: (E)-3-(2-bromophenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0143] ;
[0144] White solid, yield: 80%; mp: 63.9-64.9 ℃; 1H NMR (600 MHz, Chloroform-d) δ 8.13 (d, J = 15.9 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.60 (d,J = 8.0 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.24 - 7.19 (m, 1H), 6.46 (d, J =15.9 Hz, 1H), 5.83 (s, 1H), 2.30 (s, 6H), 1.08 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 165.27, 162.87, 147.74, 143.92, 134.32, 133.46, 131.36, 127.79,127.72, 126.11, 125.52, 120.38, 80.54, 35.29, 26.08, 14.76, 11.19. HRMS (ESI)calculated for C 19 H 23 BrNO2S [M+H] + ,408.0633; found, 408.0634.
[0145] Example 32: This example provides a compound R19, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-methylbenzaldehyde. Benzaldehyde in step (3) is replaced with trimethylacetaldehyde. The resulting compound R19 is: (E)-3-(2-methylphenyl)acrylate-1-(4,5-dimethylthiazolyl-2-yl)-2,2-dimethylpropyl ester, with the following structural formula:
[0146] ;
[0147] Pale-yellow solid, yield: 80%; mp: 52.6-53.6 ℃; 1H NMR (600 MHz, Chloroform-d) δ 8.04 (d, J = 15.8 Hz, 1H), 7.59 (d, J = 7.7 Hz, 1H), 7.28 (d,J = 7.5 Hz, 1H), 7.23 - 7.17 (m, 2H), 6.45 (d, J = 15.9 Hz, 1H), 5.84 (s,1H), 2.43 (s, 3H), 2.31 (s, 6H), 1.07 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ166.06, 163.10, 147.71, 143.33, 137.81, 133.21, 130.84, 130.22, 126.43,126.36, 126.07, 118.47, 80.33, 35.26, 26.08, 19.75, 14.79, 11.22. HRMS (ESI)calculated for C 20 H 26 NO2S [M+H] + ,344.1684; found, 344.1684.
[0148] Example 33: This example provides a compound R20, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 4-methoxybenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R20 is (E)-3-(4-methoxyphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridine-4-yl)methyl ester, with the following structural formula:
[0149] ;
[0150] Pale-yellow solid, yield: 76%; mp: 53.7-54.7 ℃; 1H NMR (400 MHz, CDCl3) δ 8.58 (d, J = 6.2 Hz, 2H), 7.73 (d, J = 15.9 Hz, 1H), 7.47 (d, J =8.8 Hz, 2H), 7.40 (d, J = 6.2 Hz, 2H), 7.05 (s, 1H), 6.87 (d, J = 8.8 Hz, 2H), 6.42 (d, J = 16.0 Hz, 1H), 3.79 (s, 3H), 2.28 (s, 3H), 2.27 (s, 3H). 13 CNMR (101 MHz, CDCl3) δ 165.51, 162.43, 161.82, 150.09, 148.82, 146.99,146.50, 130.08, 127.78, 126.71, 121.51, 114.42, 113.97, 72.98, 55.38, 14.72,11.27. HRMS (ESI) calculated for C 21 H 21 N₂O₃S [M+H] + ,381.1273; found, 381.1266.
[0151] Example 34: This example provides a compound R21, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 4-chlorobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R21 is obtained: (E)-3-(4-chlorophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0152] ;
[0153] Pale-yellow solid, yield: 76%; mp: 116.5-117.5 ℃; 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 6.2 Hz, 2H), 7.73 (d, J = 16.0 Hz, 1H), 7.47 (d, J =8.6 Hz, 2H), 7.41 (d, J = 6.3 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 7.06 (s,1H), 6.54 (d, J = 16.0 Hz, 1H), 2.32 (s, 3H), 2.30 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 164.99, 162.06, 150.17, 148.95, 146.72, 145.33, 136.79, 132.47,129.48, 129.30, 127.95, 121.51, 117.25, 73.25, 14.74, 11.32. HRMS (ESI)calculated for C 20 H 18 ClN2O2S [M+H] + ,385.0777; found, 385.0763.
[0154] Example 35: This example provides a compound R22, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 4-(trifluoromethyl)benzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R22 is (E)-3-(4-trifluoromethylphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0155] ;
[0156] Pale-yellow solid, yield: 76%; mp: 67.9-68.9 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 6.2 Hz, 2H), 7.78 (d, J = 16.0 Hz, 1H), 7.62 (s, 4H), 7.41 (d, J = 6.2 Hz, 2H), 7.06 (s, 1H), 6.63 (d, J = 16.0 Hz, 1H), 2.30 (s, 3H), 2.28 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.66, 161.86, 150.15, 148.97,146.60, 144.80, 137.31, 132.16 (q, J = 32.32 Hz), 128.43, 128.02, 125.92 (q, J = 4.04 Hz), 123.74 (q, J = 273.71 Hz), 121.50, 119.68, 119.31, 73.39,14.68, 11.25. 19 F NMR (377 MHz, CDCl3) δ -62.89. HRMS (ESI) calculated forC 21 H 18 F3N2O2S [M+H] + ,419.1041; found, 419.1042.
[0157] Example 36: This example provides a compound R23, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 4-bromobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R23 is (E)-3-(4-bromophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0158] ;
[0159] Yellow viscose oil, yield: 76%; 1 H NMR (400 MHz, CDCl3) δ 8.62 (d, J =5.1 Hz, 2H), 7.72 (d, J = 15.9 Hz, 1H), 7.54 (d, J = 8.1 Hz, 2H), 7.42 (d, J= 4.8 Hz, 4H), 7.06 (s, 1H), 6.56 (d, J = 15.9 Hz, 1H), 2.33 (s, 3H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.99, 162.03, 150.17, 148.96, 146.72,145.41, 132.90, 132.28, 129.68, 127.96, 125.20, 121.52, 117.37, 73.27, 14.74,11.33. HRMS (ESI) calculated for C 20 H 18 BrN2O2S [M+H] + ,429.0272; found,429.0274.
[0160] Example 37: This example provides a compound R24, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 4-methylbenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R24 is obtained: (E)-3-(4-methylphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0161] ;
[0162] Reddish-brown solid, yield: 76%; mp: 61.7-62.7 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 6.2 Hz, 2H), 7.77 (d, J = 16.0 Hz, 1H), 7.45 (d, J =8.1 Hz, 2H), 7.42 (d, J = 6.1 Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 7.07 (s,1H), 6.53 (d, J = 16.0 Hz, 1H), 2.37 (s, 3H), 2.32 (s, 3H), 2.31 (s, 3H). 13 CNMR (101 MHz, CDCl3) δ 165.42, 162.34, 150.12, 148.88, 146.94, 146.88,141.41, 131.29, 129.74, 128.36, 127.84, 121.53, 115.51, 73.08, 21.55, 14.75,11.32. HRMS (ESI) calculated for C21 H 21 N₂O₂S [M+H] + ,365.1323; found, 365.1321.
[0163] Example 38: This example provides a compound R25, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-methoxybenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R25 is (E)-3-(2-methoxyphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0164] ;
[0165] Pale-yellow solid, yield: 76%; mp: 47.8-48.8 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 6.2 Hz, 2H), 8.09 (d, J = 16.1 Hz, 1H), 7.49 (dd, J =7.7, 1.7 Hz, 1H), 7.41 (d, J = 6.4 Hz, 2H), 7.36 - 7.30 (m, 1H), 7.07 (s,1H), 6.93 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 16.1Hz, 1H), 3.85 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ165.81, 162.47, 158.61, 150.08, 148.80, 147.03, 142.45, 132.09, 129.42,127.79, 122.93, 121.55, 120.75, 117.05, 111.22, 72.98, 55.51, 14.72, 11.28.HRMS (ESI) calculated for C 21 H 21 N₂O₃S [M+H] + ,381.1273; found, 381.1277.
[0166] Example 39: This example provides a compound R26, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-chlorobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R26 is (E)-3-(2-chlorophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0167] ;
[0168] White solid, yield: 76%; mp: 113.7-114.7 ℃; 1 H NMR (400 MHz, CDCl3) δ8.62 (d, J = 6.2 Hz, 2H), 8.24 (d, J = 16.0 Hz, 1H), 7.65 (dd, J = 7.4, 2.0Hz, 1H), 7.44 (d, J = 6.2 Hz, 2H), 7.41 (dd, J = 7.6, 1.7 Hz, 1H), 7.34 -7.27 (m, 2H), 7.09 (s, 1H), 6.58 (d, J = 16.0 Hz, 1H), 2.32 (s, 3H), 2.30 (s,3H). 13 C NMR (101 MHz, CDCl3) δ 164.73, 162.09, 150.17, 148.89, 146.71, 142.49,135.21, 132.19, 131.57, 130.27, 127.92, 127.75, 127.18, 121.50, 119.21,73.36, 14.73, 11.30. HRMS (ESI) calculated for C 20 H 18 ClN2O2S [M+H] + ,385.0777;found, 385.0783.
[0169] Example 40: This example provides a compound R27, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-(trifluoromethyl)benzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R27 is obtained: (E)-3-(2-trifluoromethylphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0170] ;
[0171] White solid, yield: 76%; mp: 63.8-64.8 ℃; 1 H NMR (400 MHz, CDCl3) δ8.60 (d, J = 6.1 Hz, 2H), 8.18 (d, J = 2.3 Hz, 1H), 7.70 (dd, J = 15.6, 7.8Hz, 2H), 7.55 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.41 (d, J = 6.2Hz, 2H), 7.06 (s, 1H), 6.53 (d, J = 15.8 Hz, 1H), 2.30 (s, 3H), 2.28 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 164.28, 162.02, 150.17, 148.90, 146.65, 142.12 (q,J = 2.02 Hz), 132.77 (q,J = 2.02 Hz), 132.19, 130.10, 129.03 (q, J = 30.3Hz), 127.95, 127.92, 126.27 (q, J = 5.05 Hz), 123.87, (q, J = 274.72 Hz), 121.47, 120.92, 73.49, 14.69, 11.25. 19 F NMR (377 MHz, CDCl3) δ -58.73. HRMS(ESI) calculated for C 21 H 18 F3N2O2S [M+H] + ,419.1041; found, 419.1043.
[0172] Example 41: This example provides a compound R28, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-fluorobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R28 is (E)-3-(2-fluorophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0173] ;
[0174] Pale-yellow solid, yield: 76%; mp: 96.8-97.8 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.61 (s, 2H), 7.91 (d, J = 16.2 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.42 (d, J = 5.2 Hz, 2H), 7.36 (q, J = 7.1 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 10.1 Hz, 1H), 7.07 (s, 1H), 6.67 (d, J = 16.2 Hz, 1H), 2.31 (s,3H), 2.29 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 164.06, 161.09, 160.46 (d, J =255.53 Hz), 149.08, 147.85, 145.74, 138.44 (d, J = 3.03 Hz), 131.25 (d, J =9.09 Hz), 128.36 (d, J = 3.03 Hz), 126.90, 123.52 (d, J = 4.04 Hz), 121.06(d, J = 12.12 Hz), 120.49, 118.22 (d, J = 7.07 Hz), 115.27 (d, J = 22.22 Hz),72.23, 13.68, 10.25. 19 F NMR (377 MHz, CDCl3) δ -113.67. HRMS (ESI) calculated for C 20 H 18 FN2O2S [M+H] +,369.1073; found, 369.1075.
[0175] Example 42: This example provides a compound R29, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-bromobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R29 is obtained: (E)-3-(2-bromophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0176] ;
[0177] Pale-yellow viscose oil, yield: 76%; 1 H NMR (400 MHz, CDCl3) δ 8.58 (d,J = 6.1 Hz, 2H), 8.17 (d, J = 15.9 Hz, 1H), 7.58 (dd, J = 12.7, 7.9 Hz, 2H), 7.41 (d, J = 6.3 Hz, 2H), 7.29 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.06 (s, 1H), 6.50 (d, J = 15.9 Hz, 1H), 2.28 (s, 3H), 2.27 (s, 3H). 13 C NMR(101 MHz, CDCl3) δ 164.61, 162.11, 150.13, 148.87, 146.73, 145.07, 133.94,133.53, 131.73, 127.93, 127.86, 127.81, 125.64, 121.51, 119.37, 73.36, 14.73,11.31. HRMS (ESI) calculated for C 20 H 18 BrN2O2S [M+H] + ,429.0272; found,429.0274.
[0178] Example 43: This example provides a compound R30, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-methylbenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R30 is obtained: (E)-3-(2-methylphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0179] ;
[0180] Pale-yellow solid, yield: 76%; mp: 65.2-66.2 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 6.2 Hz, 2H), 8.11 (d, J = 15.9 Hz, 1H), 7.58 (d, J =8.4 Hz, 1H), 7.43 (d, J = 6.3 Hz, 2H), 7.29 (dd, J = 8.4, 2.0 Hz, 1H), 7.20(t, J = 7.6 Hz, 2H), 7.09 (s, 1H), 6.51 (d, J = 15.9 Hz, 1H), 2.43 (s, 3H), 2.31 (s, 3H), 2.30 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 165.32, 162.30, 150.14,148.87, 146.88, 144.52, 137.99, 132.87, 130.94, 130.59, 127.85, 126.52,126.44, 121.52, 117.47, 73.21, 19.76, 14.74, 11.30. HRMS (ESI) calculated forC 21 H 21 N₂O₂S [M+H] + ,365.1323; found, 365.1325.
[0181] Example 44: This example provides a compound R31, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2,3-dimethoxybenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R31 is obtained: (E)-3-(2,3-dimethoxyphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0182] ;
[0183] Pale-yellow solid, yield: 76%; mp: 73.2-74.2 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.76 (d, J = 2.3 Hz, 1H), 8.56 (dd, J = 4.8, 1.7 Hz, 1H), 8.10 (d, J= 16.1 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.28 (dd, J = 8.1, 5.0 Hz, 1H),7.17 - 7.11 (m, 2H), 7.04 (t, J = 8.0 Hz, 1H), 6.93 (d, J = 7.4 Hz, 1H), 6.59(d, J = 16.2 Hz, 1H), 3.84 (s, 6H), 2.31 (s, 3H), 2.28 (s, 3H). 13 C NMR (101MHz, CDCl3) δ 165.54, 163.00, 153.17, 149.78, 148.89, 141.49, 135.08, 134.13,128.24, 127.50, 124.21, 123.45, 119.39, 118.03, 114.45, 72.65, 61.38, 55.91,14.73, 11.27. HRMS (ESI) calculated for C 22 H 23 N₂O₄S [M+H] + , 411.1378; found,411.1372.
[0184] Example 45: This example provides a compound R32, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2,4-dimethoxybenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. Compound R32 is obtained: (E)-3-(2,4-dimethoxyphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridine-4-yl)methyl ester, with the following structural formula:
[0185] ;
[0186] Pale-yellow solid, yield: 76%; mp: 92.4-93.4 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 2.4 Hz, 1H), 8.55 (dd, J = 4.9, 1.7 Hz, 1H), 7.99 (d, J= 16.1 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.29 (d,J = 3.4 Hz, 1H), 7.13 (s, 1H), 6.55 (d, J = 16.1 Hz, 1H), 6.48 (dd, J = 8.6,2.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 2.30 (s, 3H), 2.28 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 166.26, 163.32, 163.14, 160.15,149.61, 148.83, 148.75, 142.16, 135.03, 134.34, 130.96, 127.38, 123.41,116.19, 114.38, 105.41, 98.38, 72.27, 55.47, 55.44, 14.69, 11.21. HRMS (ESI)calculated for C 22 H 23 N₂O₄S [M+H] + , 411.1378; found, 411.1373.
[0187] Example 46: This example provides a compound R33, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2-methoxybenzaldehyde. Benzaldehyde in step (3) is replaced with 4-(trifluoromethyl)benzaldehyde. Compound R33 is obtained: (E)-3-(2-methoxyphenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(4-trifluoromethylphenyl)methyl ester, with the following structural formula:
[0188] ;
[0189] Pale-yellow solid, yield: 76%; mp: 84.8-85.8 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 16.2 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.63 (d, J =8.5 Hz, 2H), 7.52 (dd, J = 7.7, 1.7 Hz, 1H), 7.41 - 7.32 (m, 1H), 7.16 (s,1H), 7.01 - 6.88 (m, 2H), 6.69 (d, J = 16.1 Hz, 1H), 3.88 (s, 3H), 2.32 (s,3H), 2.31 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 165.89, 163.35, 158.62, 148.79,142.21, 131.96, 130.75, 130.43, 129.37, 127.49, 125.68, 125.65, 125.61,125.57, 125.35, 123.10, 122.64, 120.75, 117.35, 111.24, 73.87, 55.51, 14.72,11.24. 19 F NMR (376 MHz, CDCl3) δ -62.65. HRMS (ESI) calculated for C 23 H 21 F3NO3S[M+H] + , 448.1194; found, 448.1193.
[0190] Example 47: This example provides a compound R34, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 2,4-dichlorobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R34 is (E)-3-(2,4-dichlorophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0191] ;
[0192] Pale-yellow solid, yield: 76%; mp: 96.2-97.2 ℃; 1 H NMR (400 MHz, CDCl3) δ 8.62 (d, J = 6.2 Hz, 2H), 8.14 (d, J = 16.0 Hz, 1H), 7.58 (d, J =8.5 Hz, 1H), 7.44 (d, J = 2.1 Hz, 1H), 7.42 (d, J = 6.1 Hz, 2H), 7.28 (d, J =7.7 Hz, 1H), 7.07 (s, 1H), 6.55 (d, J = 16.0 Hz, 1H), 2.32 (s, 3H), 2.30 (s,3H). 13 C NMR (101 MHz, CDCl3) δ 164.52, 161.89, 149.99, 148.96, 146.81,141.28, 136.94, 135.80, 130.83, 130.14, 128.49, 127.99, 127.67, 121.57,119.64, 73.42, 14.70, 11.29. HRMS (ESI) calculated for C 20 H 17 Cl2N2O2S [M+H] + ,419.0388; found, 419.0375.
[0193] Example 48: This example provides a compound R35, which differs from Example 1 only in that triethyl 2-phosphate acetate in step (1) is replaced with triethyl phosphonoacetate and benzaldehyde is replaced with 3-chlorobenzaldehyde. Benzaldehyde in step (3) is replaced with 4-pyridinecarboxaldehyde. The resulting compound R35 is: (E)-3-(3-chlorophenyl)acrylate-(4,5-dimethylthiazolyl-2-yl)(pyridin-4-yl)methyl ester, with the following structural formula:
[0194] ;
[0195] Yellow solid, yield: 76%; mp: 107.0-108.0 ℃; 1 H NMR (400 MHz, CDCl3)δ 8.60 (d, J = 5.1 Hz, 2H), 7.71 (d, J = 16.0 Hz, 1H), 7.52 (s, 1H), 7.41 (d,J = 4.9 Hz, 3H), 7.33 (dt, J = 15.3, 7.9 Hz, 2H), 7.06 (s, 1H), 6.56 (d, J =16.0 Hz, 1H), 2.31 (s, 3H), 2.29 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 164.78,161.95, 149.84, 148.96, 147.05, 145.17, 135.78, 135.06, 130.67, 130.24,128.02, 126.48, 123.95, 121.63, 118.16, 73.28, 14.69, 11.29. HRMS (ESI)calculated for C 20 H 18 ClN2O2S [M+H] + , 385.0777; found, 385.0782.
[0196] Example of efficacy verification: Antifungal activity study of α,β-unsaturated acrylate derivatives containing thiazole fragments prepared in the embodiments of the present invention:
[0197] Experimental subjects: compounds R1-R35, A1-A13, with boscalid and cyazofamid as positive controls;
[0198] Experimental Methods: The linear mycelial growth rate method was used to determine the in vitro inhibitory activity against eight tested plant pathogenic fungi: *Valsa mali* (apple rot causal agent), *Sclerotinia sclerotiorum* (sclerotinia sclerotiorum), *Rhizoctonia solani* (rhizoctonia solani), *Alternaria alternata* (alternaria alternata), *Fusarium graminearum* (wheat scab), *Curvularialunata* (crescent-shaped sclerotium), *Phytophthora capsici* (capsici of pepper), and *Sclerotium rolfsii* (sclerotium rolfsii). The selected fungi were provided by the Plant Disease Control Laboratory of Anhui Agricultural University.
[0199] Preliminary screening was conducted at a concentration of 50 mg / L. The test compound was completely dissolved in a 5% DMSO aqueous solution. The test solution was then rapidly mixed with PDC medium to obtain the drug-containing medium. This medium was poured into sterilized petri dishes and cooled for later use. The tested plant pathogenic fungi (5 mm in diameter) were inoculated into the above petri dishes, with three replicates per test group. After incubation at 25 ℃ for 72 h, the colony diameter (mm) was measured using the cross-crossing method, and the mycelial growth inhibition rate (IR) was calculated.
[0200] IR(%)=[(d c -d o )-(d s -d o )] / (d c -d o )×100;
[0201] Where, d o d represents the initial diameter of the mycelial cake. c The colony diameter of the control group (culture medium without added compounds) is shown in d. s The value represents the colony diameter in the drug-treated culture medium group. The results are shown in Tables 1 and 2 below.
[0202] Table 1
[0203]
[0204] Table 2
[0205]
[0206] In Tables 1 and 2: Phe: Cyazofamid, Bos: Bos: Cyazofamid; a The value is the average standard deviation of three replicates; b V. mValsa mali, the fungus causing apple rot; cSs Sclerotinia sclerotiorum, the sclerotiorum pathogen; d R. sRhizoctonia solani, the pathogen of Rhizoctonia solani; e Aa Alternaria alternata, Alternaria alternata; f F. gFusarium graminearum, a type of wheat germ fungus; g Cl Curvularia lunata, Crescentella; h P. c.Phytophthora capsica, Phytophthora capsicae; i Sr Sclerotium rolfsiii, a neatly arranged small sclerotium;
[0207] Activity screening results analysis: Preliminary bioassays revealed the in vitro inhibitory activity spectrum of the target compound against eight plant pathogenic fungi and oomycetes. Preliminary screening identified compound R7 (R... 1 = H, R 2 = 4Py, R 3 = H) is a promising lead compound. At a test concentration of 50 mg / L, this derivative exhibited significant inhibitory activity, with growth inhibition rates exceeding 71.72% against four of the eight tested bacterial strains. Notably, R7 showed good inhibition (88.92%) against *Valsa mali*, the causal agent of apple rot, and also demonstrated good activity (81.22%) against *Sclerotium rolfsii*. These results suggest that R7 could serve as an ideal lead compound for further structural optimization of α,β-unsaturated acrylate derivatives containing thiazole fragments.
[0208] Subsequently, using R7 as a structural template, halogen, -CH3, -OCH3, -CF3, and other substituents were systematically introduced at different positions on the terminal benzene ring to design and synthesize derivatives R20-R35. However, bioassay results showed that, under the same conditions, most heteroatom-modified derivatives exhibited only limited activity enhancement compared to R7, and the overall improvement effect was not significant.
[0209] These findings have driven systematic structure-activity relationship studies of R7, mainly including the following optimization strategies: exploring α-methyl substitution modes to prepare compounds A1-A6; introducing substituents such as -F, -Cl, and -CH3 at different positions on the terminal benzene ring to obtain derivatives A7-A13; encouragingly, the introduction of α-methyl substituents into compound R7 significantly enhanced its overall antifungal activity. The optimized derivative A6 showed superior inhibitory activity against *Phytophthora indicum* (89.64% vs 88.92%), *Sclerotinia sclerotiorum* (94.12% vs 79.32%), *Rhizoctonia solani* (99.18% vs 71.72%), and *Phytophthora capsici* (85.48% vs 40.20%) compared to R7.
[0210] Based on the above-described preferred embodiments of the present invention, and through the foregoing description, those skilled in the art can make various changes and modifications without departing from the inventive concept. The technical scope of this invention is not limited to the contents of the specification.
Claims
1. An α,β-unsaturated acrylate derivative containing a thiazole fragment, characterized in that, The general structural formula of the α,β-unsaturated acrylate derivatives is: ; Among them, R 1 One or more substituents are selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, and halo-C1-C6 alkyl; when R 1 When there are multiple substituents, R at different positions 1 Same or different; R 2 It is selected from any one of substituted or unsubstituted aryl, C1-C8 alkyl, anthracel, and pyridyl; the substituent in the substituted or unsubstituted aryl is selected from one or more of halogen, C1-C6 alkyl, C1-C6 alkoxy, phenoxy, phenyl, and halo-C1-C6 alkyl. R 3 It is selected from any one of hydrogen, halogen, and C1-C6 alkyl.
2. The α,β-unsaturated acrylate derivative containing a thiazole fragment according to claim 1, characterized in that, R 1 It is selected from one or more of hydrogen, fluorine, chlorine, bromine, iodine, methyl, methoxy, and trifluoromethyl; R 2 It is selected from any one of substituted or unsubstituted phenyl, 4-phenoxyphenyl, biphenyl, tert-butyl, anthracene-9-yl, pyridin-3-yl, and pyridin-4-yl; the substituent in the substituted or unsubstituted phenyl is selected from one or more of fluorine, chlorine, bromine, iodine, methyl, methoxy, and trifluoromethyl. R 3 Selected from hydrogen or methyl.
3. The α,β-unsaturated acrylate derivative containing a thiazole fragment according to claim 2, characterized in that, R 1 It is selected from one or more of hydrogen, fluorine, chlorine, bromine, iodine, and methoxy; R 2 Selected from any one of pyridin-4-yl or substituted phenyl groups; R 3 Selected from methyl.
4. A method for preparing an α,β-unsaturated acrylate derivative containing a thiazole fragment as described in any one of claims 1-3, characterized in that, Includes the following steps: Under a protective atmosphere, R 3 The group-substituted 2-phosphonoacetic acid triethyl ester and the base are dissolved in the first organic solvent and react with R 1 The mixed reaction of substituted benzaldehydes yields intermediate B; ; Intermediate B and sodium hydroxide were mixed in an ethanol-water solvent and dehydrated to obtain intermediate C; ; Under a protective atmosphere, using 4,5-dimethylthiazole as a raw material, it is dissolved in a second organic solvent along with an alkali and R. 2 The mixed reaction of substituted formaldehydes yields intermediate D; ; Intermediate C, catalyst, intermediate D, condensing agent and base are dissolved in a third organic solvent to carry out a condensation reaction to obtain the target product α,β-unsaturated acrylate derivative. ; Among them, R 1 R 2 R 3 The definition of R as described in any one of claims 1-3 1 R 2 R 3 The definitions are the same.
5. The method for preparing α,β-unsaturated acrylate derivatives containing thiazole fragments according to claim 4, characterized in that, The catalyst is 4-dimethylaminopyridine.
6. The method for preparing α,β-unsaturated acrylate derivatives containing thiazole fragments according to claim 4, characterized in that, The condensing agent is any one of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, and N-hydroxysuccinimide.
7. The method for preparing α,β-unsaturated acrylate derivatives containing thiazole fragments according to claim 4, characterized in that, The base is selected from any one of triethylamine, pyridine, potassium carbonate, cesium carbonate, sodium hydride, and n-butyllithium.
8. The use of an α,β-unsaturated acrylate derivative containing a thiazole fragment as described in any one of claims 1-3 in the preparation of an antifungal drug.
9. The application according to claim 8, characterized in that, The fungi include one or more of the following: apple rot fungus, sclerotium rot fungus, rhizoctonia solani fungus, Alternaria alternata, Fusarium graminearum, Curvularia crescentis, Phytophthora capsici, and Sclerotium sclerotiorum.
10. An antifungal drug, characterized in that, The antifungal drug comprises, as any one of claims 1-3, an α,β-unsaturated acrylate derivative containing a thiazole fragment as the active pharmaceutical ingredient; the fungus comprises one or more of the following: apple rot fungus, sclerotinia sclerotiorum, rhizoctonia solani, Alternaria alternata, Fusarium graminearum, Curvularia crescentis, Phytophthora capsici, and Sclerotium sclerotiorum.
